Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01941199 | Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects | PHASE1 | COMPLETED | 36 | — | — | Jul 1, 2013 | - | Nov 27, 2013 | 1 | South Korea |
| Arm | Type | Description |
|---|---|---|
| D → M → D+M | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| D → D+M → M | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| M → D → D+M | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| M → D+M → D | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| D+M → M → D | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| D+M → D → M | EXPERIMENTAL | D : DA-1229 5mg qd, M : metformin 1000mg bid |
| Name | Type | Description |
|---|---|---|
| DA-1229 | DRUG | - |
| metformin | DRUG | - |
| DA-1229 + metformin | DRUG | - |
Inclusion Criteria: * Age between 20 to 45, healthy male subjects(at screening) * Body weight between 55kg - 90kg, BMI between 18.0 - 27.0 * FPG 70-125mg/dL glucose level(at screening) * Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed ...